Realhearts CEO Elected to the ISMCS Board of Trustees
Press release 20 May, 2022
Realheart's CEO Ina Laura Perkins has been elected to the Board of Trustees of the International Society for Mechanical Circulatory Support, ISMCS. The announcement was made at the society's annual conference in Hannover, Germany, May 24 to 27.
The ISMCS is an international forum for discussion of the research, development, clinical use and social acceptance of rotary blood pumps and related forms of mechanical circulatory support. The aim is to improve the quality of life for patients and provide cost-effective availability of emerging therapies.
At least once a year, ISMCS holds an international meeting, alternating amongst Europe, the US and Japan. In collaboration with the International Federation of Artificial Organs, ISMCS also publishes the journal Artificial Organs, which is a platform for discussing the current state of research.
Realheart's partner professor Libera Fresiello from Belgium is also a member of the board of ISMCS.
''It is a great honour to be among these extremely knowledgeable people and to represent Swedish research in this context. I look forward to sharing their vast collective knowledge and to sharing my own lessons learned in developing Realheart® TAH'' said Ina Laura Perkins.
Ina Laura Perkins has worked with medical innovation throughout her professional career. Prior to joining Realheart in 2017, she worked as a research manager at Calon Cardio-Technology. She started her academic career in stem cell research and completed her PhD at Swansea University Medical School and holds an Executive MBA from Stockholm School of Economics.
''It is our pleasure to welcome Ina Laura Perkins to the Board. We look forward to her being a bridge between the industry and research field with her outstanding experience and knowledge in developing a total artificial heart and joining us in promoting the mechanical circulatory support field throughout the world,'' said Professor Toru Masuzawa, President of the ISMCS.
For more information please contact:
Ina Laura Perkins, CEO
Phone: +46(0)70 406 49 21
E-mail: inalaura.perkins@realheart.se
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, Phone: +46 11 32 30 732, email: ca@skmg.se
Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart® TAH has a unique, patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation. A unique concept in the medical technology world.
